Astex Pharmaceuticals, Inc., formerly SuperGen, Inc. is a pharmaceutical company is primarily engaged in the discovery and development of small molecule therapeutics with a focus on oncology and hematology. The Company is developing a pipeline of medicines for partnership with pharmaceutical companies. The Company�s two lead internal programs are AT13387, a HSP 90 inhibitor, and SGI-110, a second generation hypomethylating agent. The third product in its clinical pipeline is amuvatinib (MP-470), its multi-targeted kinase inhibitor and Deoxyribonucleic acid (DNA) repair suppressor. Using its fragment-based drug discovery platform, Pyramid, Astex Therapeutics Limited (ATL), a wholly owned subsidiary, has built a pipeline of molecularly-targeted drugs for large pharmaceutical partners and internal development that are at various stages of clinical, pre-clinical and early discovery development. On July 20, 2011, it completed the acquisition of ATL.